Elagolix

Generic Name
Elagolix
Brand Names
Oriahnn 28 Day Kit, Orilissa
Drug Type
Small Molecule
Chemical Formula
C32H30F5N3O5
CAS Number
834153-87-6
Unique Ingredient Identifier
5B2546MB5Z
Background

Elagolix has been used in trials studying the basic science and treatment of Endometriosis, Folliculogenesis, Uterine Fibroids, Heavy Uterine Bleeding, and Heavy Menstrual Bleeding. As of 24 July 2018, however, the U.S. Food and Drug Administration (FDA) approved AbbVie's elagolix under the brand name Orilissa as the first and only oral gonadotropin-releasin...

Indication

用于治疗子宫内膜异位症并伴有中度至重度疼痛。

Associated Conditions
Heavy Menstrual Bleeding, Moderate to severe pain
Associated Therapies
-
biopharmadive.com
·

Endometriosis drug research, long underfunded, confronts familiar problems in women's health

Ally Schott's early endometriosis diagnosis at 12 led to limited treatment options and self-taught research. Despite its prevalence affecting 10% of women globally, endometriosis remains underfunded and poorly understood, with only two new drugs approved in the U.S. for pain management in the past decade. Women's health research generally suffers from insufficient funding and information deficits, hindering drug development. Recent federal efforts, including a $100 million investment by the Biden administration, aim to address these gaps, but future priorities under a new administration remain uncertain.
© Copyright 2024. All Rights Reserved by MedPath